Neervannan Seshadri, chief operating officer of Tarsus Pharmaceuticals (NASDAQ:TARS), sold 8,366 shares of the company's common stock on March 4, 2026, at $76.67 per share, for a total consideration of $641,421.
The disposition was carried out via a pre-arranged Rule 10b5-1 trading plan that Seshadri established on November 13, 2025. Following the sale, Seshadri retains direct ownership of 70,817 shares in Tarsus. In addition, he indirectly holds 475 shares through his daughter.
At the time the sale was reported, the stock was trading near $74.90, after having risen roughly 72% over the past year, according to InvestingPro data. InvestingPro analysis also indicates the stock sits on its Most Undervalued list based on a Fair Value comparison, and readers are directed to the platform's Pro Research Report for expanded coverage across more than 1,400 U.S. equities.
The insider transaction comes as Tarsus reported robust fourth-quarter 2025 financial results. For the quarter, the company recorded net product sales of $151.7 million and net product sales of $451.4 million for the full year. Management attributed the year-over-year revenue and profitability gains primarily to the performance of the company’s leading product, XDEMVY. Despite the strong results, the shares saw a modest dip in aftermarket trading following the announcement.
The company’s latest quarter underscores a period of notable growth driven by product demand. The reporting does not include any updates from analyst firms regarding upgrades or downgrades in response to the results or the insider sale.
Summary of the transaction and context:
- Insider: Neervannan Seshadri, COO of Tarsus Pharmaceuticals
- Shares sold: 8,366
- Sale price: $76.67 per share
- Total value: $641,421
- Post-sale direct holdings: 70,817 shares; indirect holdings through family: 475 shares
- Trading plan: Rule 10b5-1, adopted November 13, 2025
Investors assessing Tarsus may weigh the insider sale alongside the company's recent top-line growth concentrated in its flagship product, and consider the stock's current market level relative to the reported sale price and InvestingPro's Fair Value assessment.